Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS)

Part of book or chapter of book English OPEN
Poluzzi, Elisabetta; Raschi, Emanuel; Piccinni, Carlo; Ponti, Fabrizio De;
  • Publisher: InTech
  • Related identifiers: doi: 10.5772/50095

Pharmacovigilance is a clinically oriented discipline, which may guide appropriate drug use through a balanced assessment of drug safety. Although much has been done in recent years, efforts are needed to expand the border of pharmacovigilance. We have provided insig... View more
  • References (77)
    77 references, page 1 of 8

    [1] Edwards IR (2012) An agenda for UK clinical pharmacology. Pharmacovigilance. Br. J Clin Pharmacol 73: 979-982.

    [2] Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, Tuccori M, Conforti A (2010) Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf 33: 667-675.

    [3] Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, Yue P, Tsao PS, Kohane I, Roden DM, Altman RB (2011) Detecting drug interactions from adverseevent reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 90: 133-142.

    [4] Maclure M, Fireman B, Nelson JC, Hua W, Shoaibi A, Paredes A, Madigan D (2012) When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol. Drug Saf 21 Suppl 1: 50-61.

    [5] Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150-156.

    [6] Moore N (2011) Journal's withdrawal of article. Paper OK, title wrong. BMJ 342: d2732-

    [24] Hauben M, Reich L (2004) Drug-induced pancreatitis: lessons in data mining. Br. J Clin Pharmacol 58: 560-562.

    [25] Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. (2010) Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 33: 303-314.

    [26] Hauben M, Aronson JK (2009) Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 32: 99-110.

    [27] Bate A, Lindquist M, Edwards IR (2008) The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam. Clin Pharmacol 22: 127-140.

  • Related Research Results (1)
  • Metrics
Share - Bookmark